ClinicalTrials.gg
RecruitingNCT07115511CRTALVOSUpdated Aug 11, 2025

Combined Recanalization Therapy for Acute Large Vessel Occlusion Stroke

An interventional study of Surgery in Stroke, sponsored by Tianjin Huanhu Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by Tianjin Huanhu Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Dec 2024, registered Aug 2025).
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 613 studies in Stroke with a site in China — 242 open to participants now, 263 under way, 21 of them phase 3. Stroke · China.

Planned enrollment
317th of 432
64 · median 169
Started
2024
with 70 others
No phase
264 of 613
123 open now
Primary completion
2026-11
later than 113 of 262 live
Registered
514th of 613
by date

Among the 613 studies in Stroke with a site in China, this one is the 317th largest by planned enrollment of the 432 interventional ones that give a count, is one of 71 that started in 2024, is one of 264 with no phase, reaches primary completion later than 113 of the 262 other live ones, and was the 514th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

242 of the 613 studies in Stroke with a site in China are open now. Recruiting first, the newest first:

237 more — sign in →

All 242 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 613 studies in Stroke with a site in China, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to evaluate the efficacy and safety of combined recanalization therapy in patients who cannot be recanalized by acute large vessel occlusive stroke. The main questions it aims to answer are:

1、Proportion of subjects with mRs score of 0-1 at 90 days after surgery

Participants will:

1、In acute large vessel occlusive stroke, if traditional means cannot be recanalized, combined recanalization surgery (including arteriotomy and thrombectomy, cerebrovascular bypass surgery) is performed.

03

Conditions studied

  • Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18-75.
  2. According to the current guidelines, there is a MT indication.
  3. Before stroke, mRS ≤2;
  4. ASPECTS ≥6;
  5. MCA occlusion, with or without ICA occlusion;
  6. MT unsuccessful, TICI score 0-1;
  7. Time from onset to craniotomy expected to be 24 hours or less;
  8. Post-awakening stroke with mismatch between the infarct zone and the penumbra zone;

Exclusion criteria

Exclusion Criteria:

  1. Comorbid hemorrhagic vascular disease such as intracranial aneurysm or vascular malformation or other planned cerebrovascular surgery that may alter cerebral hemodynamics or lead to stroke;
  2. unstable angina or myocardial infarction, congestive heart failure within the previous 6 months;
  3. Pregnancy or perinatal period;
  4. Hematologic disorders resulting in coagulation disorders;
  5. Combination of other diseases with a of less than 2 years; and
  6. previous treatment with intracranial or extracranial vascular bypass surgery;
  7. allergy to iodine or X-ray contrast media, creatinine >3.0 mg/dl or other to arteriography;
  8. Uncontrolled diabetes mellitus, fasting blood sugar (FBS) >16.7 mmol/L;
  9. Uncontrolled hypertension with sitting systolic blood pressure >180 mmHg or sitting diastolic blood pressure >110 mmHg;
  10. Severe hepatic dysfunction, defined as serum (ALT) and/or alanine aminotransferase (AST) >3 times the ;
  11. \<100×109 /L.
  12. Received a clinical trial drug or device within 30 days prior to screening, or is participating in another clinical trial;
  13. contraindication to general anesthesia or craniotomy;
  14. other diseases or medical history that, in the investigator's judgment, may affect the efficacy or safety evaluation of this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    experiment group(surgical treatment)

    Procedure: Surgery

  • No intervention
    control group(conservative therapy)

Interventions

  • ProcedureSurgery

    Recombined recanalization surgery

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with mRs score of 0-1 at 90 days after surgery

    Time frame: 90 days after recombined recanalization surgery

Secondary outcomes

  1. Changes in NIHSS score at 24 hours after surgery, 7 days after surgery, 30 days after surgery and 90 days after surgery compared with baseline;

    Time frame: 90 days after recombined recanalization surgery

  2. The mRs score changed from baseline at 90 days after surgery

    Time frame: 90 days after recombined recanalization surgery

  3. Change from baseline in MOCA score at 90 days after surgery

    Time frame: 90 days after recombined recanalization surgery

  4. Change from baseline in MMSE score at 90 days after surgery

    Time frame: 90 days after recombined recanalization surgery

07

Study locations

1 of 1 sites recruiting
  • Tianjin Huahu Hospital
    Tianjin, Tianjin Municipality 300060, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Nov 2026, 23 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 23 months is close to that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Aug 11, 2025
StartActual
Dec 1, 2024
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07115511
Lead sponsor
Tianjin Huanhu Hospital
Responsible party
Gao Kaiming (DOC., Tianjin Huanhu Hospital) — Principal investigator
First posted
Aug 11, 2025
Start date
Dec 1, 2024
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Aug 11, 2025

Study contacts

Gao Kaiming
Contact
sunnygao_sg@163.com
+8618622301400

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion